Dyne Therapeutics Prices Upsized Public Offering of 18.98M Shares, Raising $350M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Globenewswire
- Upsized Offering: Dyne Therapeutics announced an upsized public offering of 18,980,478 shares at $18.44 per share, expected to raise $350 million, significantly enhancing its financial capacity to support ongoing R&D initiatives.
- Underwriter Selection: The offering is managed by Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities, reflecting strong market confidence in Dyne and potentially enhancing its reputation among investors.
- Transaction Timeline: The offering is expected to close on or about December 11, 2025, subject to customary closing conditions, ensuring rapid access to funds to support the company's strategic objectives.
- Future Growth Potential: Dyne focuses on therapeutics for genetically driven neuromuscular diseases, and the proceeds will advance clinical programs for myotonic dystrophy and Duchenne muscular dystrophy, further solidifying its market position in the biopharmaceutical sector.
Analyst Views on DYN
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 33.50 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 19.390
Low
11.00
Averages
33.50
High
48.00
Current: 19.390
Low
11.00
Averages
33.50
High
48.00
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
